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Early and accurate diagnosis of fetal aneuploidies is one of the 
cornerstones of fetal medicine. While invasive tests – chorionic 
villus sampling (CVS), amniocentesis, or cordocentesis – remain the 
gold standard for diagnosis of aneuploidies, there have been several 
advances in non-invasive screening tests in both the first and second 
trimesters of pregnancy. Invasive testing carries a risk of miscarriage, 
albeit low in experienced hands, but devastating especially if the 
fetus is chromosomally normal, hence the need for developments in 
non-invasive tests. Detailed first- and second-trimester ultrasound 
scans, maternal characteristics and serum markers have been part 
of standard practice for aneuploidy screening for more than two 
decades.[1-3] Non-invasive prenatal testing (NIPT) to screen for fetal 
aneuploidies by quantitative evaluation of the fetal fraction of cell-
free DNA (cfDNA) in maternal blood is a relatively new technology 
that has advanced rapidly.
The presence of a fetal fraction of cfDNA in maternal blood was 
first described in 1997,[4] and it was reported that this represents the 
entire fetal genome and can be detected as early as the first trimester 
of pregnancy. There is abundant evidence to support the efficacy of 
NIPT, using cfDNA, in screening for trisomies 21 and 18, and to a 
lesser extent trisomy 13.[5] High efficacy has also been reported by 
test manufacturers for monosomy X, sex chromosome trisomies and, 
for some tests, triploidy. As the technology advances more conditions 
are being tested for, including chromosomal microdeletions, and 
the fetal fraction of cfDNA is also being used to predict pregnancy 
complications such as pre-eclampsia.[6-8]
Concerns have been raised about the injudicious use of cfDNA 
testing, which often leads to inaccuracies in interpretation of the role 
and value of cfDNA in prenatal screening.[9,10] As a result, several 
recommendations on the use of cfDNA for prenatal testing have 
been published.[9,11-13] Adequate data on NIPT only exist for high-
risk populations, i.e. pregnant women with a risk of chromosomal 
abnormalities of >1:100; most guidelines therefore recommend NIPT 
use for this group of obstetric patients.[12,13] Guidelines also emphasise 
the importance of pretest counselling, and that NIPT is a screening 
test and management decisions should not be based on the results of 
the test alone.[9,11-13]
Objective
While the technology for fetal cfDNA testing becomes more refined 
and there is general acknowledgement of its high detection rate for 
the common aneuploidies, several recommendations have been made 
about the place of NIPT in contingency screening, in both the first 
and second trimesters. The objective of this study was therefore to 
determine the value and role of NIPT in a select South African (SA) 
population.
Methods
This was a retrospective record review of 82 patients who elected to 
have NIPT, using cfDNA, between 1 October 2013 and 30 June 2015 
at the Morningside Mediclinic Maternal and Fetal Medicine Centre 
in Johannesburg, SA. The unit is a large referral centre for patients 
accessing private healthcare, and services offered include combined 
first-trimester screening (CFTS), second-trimester anomaly ultra-
sound scans, invasive diagnostic and therapeutic procedures, and 
follow-up ultrasound scans as indicated. CFTS incorporates maternal 
characteristics, a first-trimester nuchal translucency ultrasound scan, 
and serum biochemical investigations (measurement of serum free 
beta human chorionic gonadotrophin and pregnancy-associated 
plasma protein A). The Fetal Medicine Foundation database is used 
for risk calculation in the first and second trimesters. All patients are 
counselled by the fetal medicine specialist and a genetic counsellor 
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about the limitations of screening tests, and 
based on the risk assessment, elect to have 
no further tests or procedures, NIPT and/
or an invasive diagnostic test. Obstetric care 
of the patients is provided by the referring 
clinicians.
The NIPT, with cfDNA testing, was 
done in either the first or second trimester 
using the Natera Panorama test for all 
the specimens. The Natera Panorama test 
reports on the fetal fraction of cfDNA, and 
does a risk calculation for the common 
trisomies – 21, 18 and 13, monosomy X and 
triploidy. Patient records were reviewed to 
assess the risk profile of patients who elected 
to have the test, and also to evaluate the 
results of the NIPT. Patients were contacted 
telephonically to determine the pregnancy 
outcomes.
Data were collected on the following 
parameters: demographics; details of the 
first- and/or second-trimester screening; 
results of the NIPT; any invasive tests done; 
and decisions made about the pregnancy 
in the event of abnormal test results. Study 
data were collected and managed using 
REDCap[14] electronic data capture tools 
hosted at the University of the Witwatersrand, 
Johannesburg. JMP, version 11 (SAS Institute, 
USA) was used for statistical analysis. The 
study was approved by the University of 
the Witwatersrand’s Human Research Ethics 
Committee (protocol no. M150935).
Results
During the study period, a total of 3 473 
first- and second-trimester fetal assess-
ments were done at the Morningside Centre, 
and of these patients, 82 (2.3%) elected to 
have NIPT. All had singleton pregnancies. 
The median age of the 82 patients was 36 
years (interquartile range (IQR) 31 - 39) 
(Table 1), and the median weight (n=81) 
was 62.0 kg (IQR  58.0 - 72.0). In 92.7% 
(76/82) of the cases, conception had been 
spontaneous. Overall, 28 patients (34.1%) 
had an underlying chronic medical dis-
order, most commonly thyroid disease, 
hypertensive disorders and polycystic ova-
rian syndrome.
A total of 67 patients (81.7%) had 
CFTS. The background risk for trisomy 
21 was high in 32.8% (22/67) of the 
patients, while 67.2% (45/67) were in the 
intermediate-risk group. The patients were 
assessed as screening positive on CFTS if 
the adjusted risk was either intermediate 
(1:101 - 1:1000) or high risk (>1:100) for 
the three trisomies – 21, 18 and 13. Of the 
patients who had CFTS, 44/67 (65.7%) 
screened positive for trisomy 21, with 9.0% 
(6/67) having a high adjusted risk (Table 2). 
For trisomy 18 and trisomy 13, 9% (6/67) 
screened positive in each group. Of the 67 
patients who had CFTS, 52 (77.6%) also 
had a second-trimester anomaly ultrasound 
scan. There were 14 patients who only 
had a second-trimester ultrasound scan. 
Of the total number of second-trimester 
ultrasound scans done (n=66), 14 (21.2%) 
detected a variety of markers of aneuploidy. 
Eight of these patients only had a second-
trimester ultrasound scan, and 6 had prior 
CFTS.
Overall, 82 NIPTs were done, with a 
median gestational age at the time of the 
test of 14 weeks (IQR 13 - 21); a total 
of 46 patients (56.1%) had NIPT at a 
gestational age of ≤14 weeks. The majority 
of patients elected to have NIPT based on 
positive screening on CFTS, or markers 
of aneuploidy detected on the second-
trimester ultrasound scan (Table 2). Of 
the tests done, 80/82 (97.6%) produced 
results, and the median fetal fraction of 
cfDNA was 10.5% (IQR  7.9 - 13.7). Of 
those with no results, one did not meet 
quality metrics and the other had a low 
fetal fraction of cfDNA; both were done 
in the first trimester and both pregnancies 
were a result of assisted reproduction. 
In the case where the specimen did not 
meet quality metrics, the fetal fraction of 
cfDNA was 4.8%. Anomalies suggestive 
of aneuploidy were detected on the first-
trimester ultrasound scan, and the patient 
elected to have a termination of pregnancy 
based on the ultrasound findings. There 
were no karyotype results available to 
confirm the suspicion of a chromosomal 
abnormality. In the second case with no 
NIPT result, the fetal fraction of cfDNA 
was 3.3%. Increased nuchal translucency 
was detected on the first-trimester ultra-
sound scan, and the patient declined 
inva sive testing. She subsequently had a 
spontaneous miscarriage, and karyotyping 
of the products of conception confirmed 
trisomy 18.
Of the 80 NIPT results that were repor-
ted, 79 (98.8%) indicated a low risk of 
trisomy 21 and 18. For trisomy 13, 78/80 
cases screened low risk. There were two 
abnormal NIPT results: one was reported 
as high risk for trisomy 13 and the other 
as a triploidy (Table 3). In the first case, 
a cleft palate was detected on the first-
trimester ultrasound scan, and the adjusted 
risk on CFTS was intermediate for all the 
three common trisomies. Trisomy 13 was 
confirmed on karyotyping of the products 
of conception after the patient elected to 





IQR 31 - 39
<35, n (%) 35 (42.7)






Chronic medical disorder,* n (%)
Yes 28 (34.1)
Gestational age at NIPT (wk)
Median 14
IQR 13 - 21
≤14, n (%) 46 (56)
*The most common underlying medical disorders 
were thyroid disease, hypertensive and gastrointestinal 
disorders, and polycystic ovarian syndrome.
Table 2. Indications for NIPT (N=82)
Screening with CFTS (n=67), n (%)
Low risk Intermediate risk High risk 
Trisomy 21 23 (34.3) 38 (56.7) 6 (9.0)
Trisomy 18 61 (91.0) 5 (7.5) 1 (1.5)
Trisomy 13 61 (91.0) 3 (4.5) 3 (4.5)
Second-trimester ultrasound findings (n=14),* n (%)
Marker(s) of aneuploidy detected 8 (57.1)
No marker(s) detected 6 (42.9)
Other†
Increased background risk of trisomy 21 1
*These patients only had a second-trimester ultrasound scan and no CFTS.
†Patient had an ultrasound scan at 15 weeks, and had an increased background risk of trisomy 21 based on first-trimester 
biochemistry. The CFTS risk assessment was not calculated, as she had an ultrasound scan at a later gestation.
1049       October 2016, Vol. 106, No. 10
RESEARCH
have a termination of pregnancy. In the 
case of triploidy reported on NIPT, and 
confirmed on CVS, no suspicious findings 
were detected on CFTS.
Details on pregnancy outcomes were 
available for 74/82 patients (90.2%). Of these, 
93.2% (69/74) had a live birth, 85.3% (58/68) 
delivering by caesarean section, the majority 
(44/58) elective. There were no chromosomal 
abnormalities reported for the live births. 
A total of 4 patients had a termination of 
pregnancy, 3 for confirmed chromosomal 
abnormalities as detailed above, and 1 
for spontaneous rupture of membranes 
and anhydramnios at an early, non-viable 
gestation. One patient had a spontaneous 
miscarriage and the fetus had a confirmed 
chromosomal abnormality, also described 
above.
Discussion
In this select SA population, 2.3% of patients 
screened during the study period had NIPT. 
The study sample had either an intermediate 
or a high background risk for trisomy 21, 
largely based on maternal age. The majority 
of patients elected to have NIPT, using 
cfDNA, based on either a positive screening 
result on CFTS or markers detected on the 
second-trimester anomaly ultrasound scan. 
Results of NIPT were reported in 97.6% of 
the cases, and there were 2 cases (2.5%) that 
screened positive, 1 for trisomy 13 and 1 for 
triploidy. Of the 2 cases with no results, 1 was 
confirmed as trisomy 18 on karyotyping and 
the second had no karyotype results. There 
were no reported aneuploidies among the 
cases with known birth outcomes (90.2%) at 
the end of the study.
Patient selection in our study was in line 
with recommendations in various publi-
shed guidelines. The International Society 
of Ultrasound in Obstetrics and Gyne cology 
guidelines acknowledge that ade quate 
data on NIPT exist for high-risk obstetric 
patients, and its use is therefore recommend 
for this group.[12] However, the guidelines 
further state that NIPT may be offered to 
patients who are not reassured by an inter-
mediate-risk assessment. [12] The American 
College of Obstetricians and Gynecologists 
committee opinion on cfDNA screening 
for fetal aneuploidy also cautions about the 
use of cfDNA screening in low-risk popu-
lations, as there are limited data on cost-
effectiveness in this group.[13] There were 
patients in our study who, after counselling, 
elected to have NIPT despite a low adjusted 
risk assessment. In cases where a struc-
tural anomaly is detected on ultrasound, the 
recommendation is that diagnostic testing 
should be offered instead of cfDNA screen-
ing.[13]
Overall in our study the performance 
of NIPT screening was good, in that there 
were only two cases that had no results. 
In cases where results are not reported, 
the recommendation is for patients to be 
offered detailed ultrasound assessment and 
diagnostic testing because of an increased 
risk of aneuploidy.[13] In both cases with 
no results in our study, patients declined 
invasive testing despite first-trimester 
ultrasound findings suggestive of an 
increased risk of aneuploidy. In the one case 
that screened positive on NIPT and was 
confirmed as trisomy 13 on karyotyping, 
aneuploidy was suspected based on the 
first-trimester ultra sound findings, calling 
into question the value of cfDNA screening 
in cases with obvious abnormalities on 
ultrasound. While patients were counselled 
about the need for invasive testing follow-
ing an abnormal NIPT result, or in 
cases where there were no results, some 
patients elected to have a termination of 
pregnancy based on ultrasound and NIPT 
results alone. Patients were reassured by 
negative NIPT screening results, and all 
the patients who screened negative elected 
not to have an invasive test, even those who 
had a high adjusted risk on CFTS or had 
markers detected on the second-trimester 
ultrasound scan. Regardless of the NIPT 
results, patients need to be counselled about 
the limitations of this screening test, and 
that management decisions cannot be based 
on NIPT results alone.
The value of NIPT in this select popu-
lation was that it was possible to avoid a 
number of invasive tests in the small group 
with a high adjusted risk for trisomy 21. 
As per guidelines, NIPT was not used as 
a stand-alone test, but rather had a role 
in contingency screening. However, our 
study had limitations, in that the sample 
size was small and it was conducted in a 
select population, and findings cannot be 
generalised to a wider population. Also, 
the pregnancy outcomes were not known 
in a small proportion of patients, but it is 
unlikely that aneuploidies would not have 
been reported if missed. The strengths, 
however, are that the centre where the study 
was done uses internationally recognised 
standards for CFTS and the second-
trimester anomaly ultrasound scan. Also, 
the same test, the Panorama test, was used 
for all the specimens and the fetal fraction 
of cfDNA was reported on routinely. There 
is certainly a need for larger studies in 
SA to determine the value and role of 
NIPT screening, especially in low-risk 
populations and in cases where obvious 
anomalies are detected on ultrasound.
Conclusion
In conclusion, NIPT screening, using 
cfDNA, should be offered as part of contin-
gency screening in high- and intermediate-
risk obstetric patients. Patients should be 
counselled, ideally by a genetic counsellor 
before and after the test, about the limita-
tions of NIPT screening and that manage-
ment decisions should not be made without 
invasive diagnostic testing when a result is 
abnormal.
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Table 3. Results of NIPT screening (N=82)
NIPT results Ultrasound findings  Pregnancy outcomes*
Reported results, n (%) 80/82 (97.6)
cfDNA, %
Median 10.5
IQR 7.9 - 13.7
Cases with no results, n (%) 2/82 (2.4)
 Did not meet quality 
matrix




Low cfDNA 1 (cfDNA 3.3%) Increased nuchal 
translucency
Spontaneous miscarriage
Trisomy 18 on karyotyping
Abnormal NIPT results 2/82 (2.4)
High risk for trisomy 13 1 Cleft palate Termination of pregnancy
Trisomy 13 on karyotyping
Triploidy 1 Normal Termination of pregnancy
Triploidy on karyotyping
*Pregnancy outcomes were available for 74/82 cases (69 live births, 4 terminations of pregnancy, 1 spontaneous miscarriage).
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